Hepatolenticular Degeneration: Clinical Trials

79 trials for Hepatolenticular Degeneration, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 completed, 21 recruiting, 7 active not recruiting, 7 unknown. 17 Not applicable, 11 Phase 1, 9 Phase 2, 6 Phase 3, 3 Early Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable17Completed 8, Recruiting 3, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1
Phase 111Completed 6, Active not recruiting 2, Recruiting 2, Not yet recruiting 1
Phase 29Completed 4, Active not recruiting 2, Recruiting 2, Not yet recruiting 1
Phase 36Completed 3, Terminated 2, Recruiting 1
Early Phase 13Recruiting 2, Unknown 1
Phase 43Unknown 2, Completed 1

Follow Hepatolenticular Degeneration: new trials by email Literature Review of Hepatolenticular Degeneration trials Research Report on Hepatolenticular Degeneration

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
TETA 4HCl formulation, D-Penicillamine - Wilson's Disease
Phase 3RecruitingOrphalan382026-09-032026-10-15
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
PM577a - Wilson Disease, Wilson's Disease
Phase 1 / Phase 2RecruitingPrime Medicine, Inc.422026-09-012026-10-01
Description of Renal Involvement in Wilson's Disease
full renal workup - Wilson Disease
RecruitingFondation Ophtalmologique Adolphe de Rothschild1502026-07-222026-10-01
Endocrine Dysfunction in Pediatric Wilson's Disease
Wilson's Disease
Not yet recruitingAssiut University302026-06-302025-10-06
Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
LY-M003 Injection - Wilson's Disease
Phase 1 / Phase 2Not yet recruitingLingyi Biotech Co., Ltd.182026-06-152026-07-02
Evaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
GC310 - Wilson Disease
Phase 1 / Phase 2RecruitingGeneCradle Inc152026-02-202026-11-17
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
Wilson Disease
RecruitingYale University302026-01-082026-03-05
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
Group 1: DSL101 Low dose, Group 2: DSL101 Medium dose, Group 3: DSL101 High dose - Wilsons Disease
Early Phase 1RecruitingDSciLab Co., Ltd.182025-12-312026-01-20
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
Wilson Disease
Active not recruitingPrime Medicine, Inc.302025-12-292026-05-12
Multifaceted Assessment of Patients With Wilson's Disease in a Low-Resource Setting in Upper Egypt: Service Integration, Psychosocial Burden, Dietary Practices, and the Geo-Spatial Disease Map
KAB-pB Scores - Wilson's Disease
Not yet recruitingAssiut University662025-12-012025-11-21
Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity
Preparation of forearm molds with SILFLO® silicone - Wilson Disease, D-Penicillamine
Not applicableRecruitingCentre Hospitalier Universitaire de Saint Etienne1202025-11-282026-01-23
Subclinical Myocardial Dysfunction in Children With Wilson's Disease
Echocardiography, Electrocardiography, N-terminal pro b- type natriuretic peptide - Wilson's Disease, Myocardial Dysfunction
Active not recruitingHebatullah Fawzy722025-10-012026-08-14
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
New TETA 4HCl Formulation, Standard of Care - Wilson's Disease
Phase 2CompletedOrphalan102025-07-152026-04-06
Gene Therapy for Wilson Disease Evaluated by 64Cu PET/CT
Wilson Disease
Enrolling by invitationThomas Damgaard Sandahl52025-07-082025-09-08
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
urine and blood test - Wilson Disease
RecruitingHospices Civils de Lyon302025-01-102026-01-15
Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children
Plasma Exchange, Standard Medical Treatment - Acute Liver Failure, Wilson Disease
Not applicableNot yet recruitingInstitute of Liver and Biliary Sciences, India202024-11-102024-11-21
An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease
MWAV201 - Wilson Disease
Not applicableActive not recruitingXinhua Hospital, Shanghai Jiao Tong University School of Medicine92024-10-282026-08-12
A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson Disease
LY-M003 - Wilson Disease
Early Phase 1RecruitingChaohui Yu182024-09-242026-01-23
The Exploratory Handheld Optical Coherence Tomography Study in Wilson's Disease
Diagnostic procedures - Wilson Disease
Not applicableCompletedRoyal Surrey County Hospital NHS Foundation Trust102024-08-022025-07-01
Institutional Registry of Rare Diseases
Rare Diseases, Amyloidosis
RecruitingHospital Italiano de Buenos Aires3802024-07-012026-01-14

Showing 20 of 79. Sign in to see all of them.

Narrower conditions

Metabolism, Inborn Errors (4)  ·  Rare Diseases (4)  ·  Dystonia (3)  ·  Genetic Diseases, Inborn (3)  ·  Leukodystrophy, Metachromatic (3)  ·  Ornithine Carbamoyltransferase Deficiency Disease (3)  ·  3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (2)  ·  Acidemia, isovaleric (2)  ·  Adrenal Hyperplasia, Congenital (2)  ·  Adrenoleukodystrophy (2)  ·  Anemia, Sickle Cell (2)  ·  Argininosuccinic Aciduria (2)  ·  Ataxia with vitamin E deficiency (2)  ·  Basal ganglia disease, biotin-responsive (2)

Broader conditions

Basal Ganglia Diseases (79)  ·  Brain Diseases (79)  ·  Brain Diseases, Metabolic (79)  ·  Brain Diseases, Metabolic, Inborn (79)  ·  Central Nervous System Diseases (79)  ·  Digestive System Diseases (79)  ·  Heredodegenerative Disorders, Nervous System (79)  ·  Neurodegenerative Diseases (79)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (78)  ·  Liver Diseases (78)  ·  Metal Metabolism, Inborn Errors (78)  ·  Nervous System Diseases (78)  ·  Nutritional and Metabolic Diseases (78)  ·  Metabolic Diseases (77)  ·  Movement Disorders (77)

Interventions

tetrathiomolybdate (6)  ·  Trientine (5)  ·  Standard of Care (4)  ·  Penicillamine (3)  ·  Hematologic Tests (2)  ·  gluconic acid (2)  ·  Botulinum Toxins, Type A (1)  ·  Bupropion (1)  ·  Celecoxib (1)  ·  Diagnostic Imaging (1)  ·  Diagnostic Techniques and Procedures (1)  ·  Echocardiography (1)  ·  Electrocardiography (1)  ·  Galactose (1)  ·  Genetic Testing (1)

Sponsors

Alexion Pharmaceuticals, Inc. (11)  ·  Fondation Ophtalmologique Adolphe de Rothschild (7)  ·  Orphalan (6)  ·  Assiut University (4)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (3)  ·  Ultragenyx Pharmaceutical Inc (3)  ·  Yale University (3)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Hospices Civils de Lyon (2)  ·  National Center for Research Resources (NCRR) (2)  ·  Prime Medicine, Inc. (2)  ·  Univar BV (2)  ·  Asociación Española para el Estudio del Hígado (1)  ·  Beijing Friendship Hospital (1)  ·  CENTOGENE GmbH Rostock (1)

Countries

United States (23)  ·  France (17)  ·  United Kingdom (17)  ·  China (15)  ·  Germany (11)  ·  Spain (8)  ·  Denmark (6)  ·  Poland (6)  ·  Canada (4)  ·  New Zealand (4)  ·  Austria (3)  ·  Belgium (3)  ·  Italy (3)  ·  Turkey (Türkiye) (3)  ·  Australia (2)

Top investigators

Eugene S. Swenson, MD, PhD (4)  ·  Chaohui Yu, PhD (2)  ·  George J. Brewer (2)  ·  Adrian Gadano, MD (1)  ·  Andres Lozano, MD (1)  ·  Anna Davidsson (1)  ·  Arndt Rolfs, Prof. Dr. (1)  ·  Chinchang Huange, Doctor (1)  ·  Curt Scharfe, MD, PhD (1)  ·  Eduardo Jorge Premoli, MD (1)

Results publications

PMID 21078496, PMID 22340672, PMID 25605552, PMID 28747452, PMID 28753182, PMID 28988934, PMID 30241550, PMID 30691535, PMID 31315600, PMID 31947878, PMID 32651242, PMID 34162411, PMID 34286869, PMID 34572285, PMID 35142618, PMID 35482910, PMID 35668470, PMID 35995551, PMID 36183738, PMID 37722831, PMID 37782421, PMID 38397079, PMID 38660122, PMID 39139457, PMID 39468897, PMID 40089450, PMID 40104015, PMID 40538652, PMID 41667276, PMID 41831608

NIH funding

2017 (1), 2018 (1), 2019 (1), 2025 (1), R01DK137861 (1)